Darolutamide

證據等級: L5

預測適應症: 3 個

Darolutamide: From Unspecified Original Indication to Homozygous Familial Hypercholesterolemia

One-Sentence Summary

Darolutamide's original approved indication and mechanism of action are both currently undocumented in this evidence pack (flagged as data gaps DG001/DG002). The TxGNN model predicts it may be effective for Homozygous Familial Hypercholesterolemia, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a model-only signal at this stage.

Quick Overview

Item	Content
Original Indication	Not available — no Norway licenses on file, original indication list empty
Predicted New Indication	Homozygous Familial Hypercholesterolemia
TxGNN Prediction Score	99.11%
Evidence Level	L5 (model prediction only, no supporting trials or literature)
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (DG002, High severity), and the drug's original approved indication is also not on file in this evidence pack. Without either data point, no mechanistic or disease-similarity rationale can be constructed between darolutamide and homozygous familial hypercholesterolemia at this time.

Two other candidate indications were also generated by TxGNN for this drug — multiple endocrine neoplasia (score 99.06%) and HIV infectious disease (score 99.04%) — but neither is discussed further here since the report format focuses on the top-ranked candidate. Notably, the multiple endocrine neoplasia candidate is linked to only a single terminated Phase 1 basket trial (n=2) that is not specific to that indication, and the HIV candidate has no supporting evidence at all.

Given the absence of MOA, original-indication context, and any clinical/literature evidence, this prediction should be treated as an early-stage signal requiring substantial follow-up before any pharmacological rationale can be asserted.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Norway Market Information

Darolutamide is not currently marketed in Norway (0 authorizations on file), so no product/authorization table is available.

Safety Considerations

Please refer to the package insert for safety information.

Note: TFDA/label warnings and contraindications data are currently missing and flagged as a Blocking data gap (DG001) — this prevents the drug from entering the S1 initial safety assessment stage.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (homozygous familial hypercholesterolemia) has zero supporting clinical trials or literature, and the drug currently has a Blocking safety data gap (missing TFDA warnings/contraindications) that prevents any safety pre-assessment. There is insufficient evidence to advance this candidate at this time.

To proceed, the following is needed:

TFDA label (warnings & contraindications) — required to clear the Blocking gap (DG001) before any S1 safety evaluation
Mechanism of action data from DrugBank (DG002) — needed to assess mechanistic plausibility
Confirmation of the drug's original approved indication(s)
Independent literature or trial search specific to homozygous familial hypercholesterolemia, since none currently exist in the evidence base
Re-evaluation of the lower-ranked candidates (multiple endocrine neoplasia, HIV) if TxGNN scores are revisited, as current supporting evidence is negligible or absent for both
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.